← feed

Is NCT02244489 results overdue?

Yes — results are overdue. Primary completion was 2017-03-08; the FDAAA-801 reporting deadline (2018-03-08) passed 3027 days ago and no results are posted on ClinicalTrials.gov.

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT IDNCT02244489 ↗
SponsorSierra Oncology LLC - a GSK company (INDUSTRY)
PhasePHASE1
StatusTERMINATED
Primary completion2017-03-08 (ACTUAL)
Reporting deadline2018-03-08 (completion + 365d)
Days overdue3027
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 26065552b012438a… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02244489. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →